Aimei Health Technology Co., Ltd.AFJK
Cash in trust
$12.5M
$12,488,393
Trust per share
$12.00
Redemption value
IPO
Dec 2023
—
Combination deadline
—
Not disclosed
Filings on record
120
Latest Sep 3, 2026
Overview
Aimei Health Technology Co., Ltd. is a special purpose acquisition company incorporated and registered with the SEC under CIK 0001979005. It completed its initial public offering in Dec 2023 and listing on Nasdaq. Class A shares trade under the ticker AFJK, units under AFJKU, rights under AFJKR on Nasdaq. The vehicle is sponsored by Aimei through Aimei Investment Ltd. The mandate targets technology, healthcare. IPO closed, trust funded, no definitive agreement announced.
“We intend to seek target companies that have significant and underexploited expansion opportunities in a niche sector.”
Reading the filings
Arithmetic on what Aimei Health Technology Co., Ltd. has disclosed, written the way a desk would read it. These are observations, not a rating. Nothing here scores the vehicle or implies a view on it.
Trading at a premium to trust
At $12.51 the shares trade 4.25% above the $12.00 redemption floor. Above trust the market is paying for the announced or expected deal rather than for the cash, so the premium is what is at risk if the combination does not close.
Trust versus the $10 unit
The trust holds $12.00 per public share, 20.0% above the $10.00 the units were sold at. That spread is accrued interest on the trust and, where the charter provides for it, sponsor contributions paid in to buy more time. It is the floor a public shareholder can redeem at, not a valuation of the business.
Sponsor promote
The sponsor's founder block is 437,500 shares against 1,040,332 public shares, or 29.6% of the combined count, acquired before the IPO at nominal cost. That promote is the structural dilution every public shareholder carries into a combination, and it is why the economics of a de-SPAC differ so sharply from a conventional IPO.
Underwriting
Spartan Capital led the offering. It has been named on 1 SPAC IPOs, book-running 1 of them. The syndicate has no control over whether a sponsor finds a target, but the quality of the book at pricing shapes who ends up holding the units.
Scores
Recomputed 4m agoThree readings of Aimei Health Technology Co., Ltd., each an unweighted mean of the components shown beneath it, and each component a percentile against every live SPAC rather than an absolute we invented. They describe the setup, not the merit. How they are built
Edge
ElevatedHow much does the structure protect a holder right now?
53/100
- Discount to trust8
-2.67%
- Trust accretion97
$12.00 per share
Edge reads the setup, not the business. A vehicle can score well on protection and still be a poor place to leave money once a deal closes.
FOMO
ElevatedHow much attention is this vehicle attracting right now?
67/100
- Filing activity85
6 in 30 days
- News coverage40
1 story in 30 days
- News tone50
neutral
- Premium to trust92
2.67%
Attention is not quality. FOMO rises on news volume and on the market paying above trust, both of which have preceded plenty of disappointments.
Potential
LowHow likely is this vehicle to complete a combination, and at what scale?
15/100
- Bank franchise0
1 SPAC mandates
- Trust scale5
$12M
- Stage40
searching
Potential is about execution, not about the target. It says nothing about whether the eventual deal is worth owning, because the target is usually unknown when the score is computed.
These are derived measures, not ratings of investment merit. They carry no view on the target, no price target and no recommendation, and a high score is not a reason to buy anything.
News on Aimei Health Technology Co., Ltd.
Last 90 days- Aimei Health Technology Q2 EPS $(0.03) Down From $0.07 YoYNeutral
Benzinga · 22d ago
- Aimei Health Technology Terminates The Business Combination Agreement With United Hydrogen GroupNeutral
Benzinga · 1mo ago
News sentiment
NeutralAcross 3 recent stories, weighted towards the newest. Scored by our own headline classifier using finance- and SPAC-specific terms. It reads what a story is about, not what the shares are worth.
SEC filing history
Free tier: filings older than 24 hours- 8-K
Current report
Items 2.03, 9.01 · Accession 0001493152-26-041316
- 8-K
Notice of delisting or failure to satisfy a listing rule
Items 3.01, 9.01 · Accession 0001493152-26-040044
- 10-Q
Quarterly report
Accession 0001493152-26-037588
- SCHEDULE 13G/A
Amended beneficial ownership report (passive)
Accession 0001604488-26-000081
- 8-K
Current report
Items 2.03, 9.01 · Accession 0001493152-26-036336
- SCHEDULE 13G/A
Amended beneficial ownership report (passive)
Accession 0001628280-26-053520
- 8-K
Termination of a material definitive agreement; Regulation FD disclosure
Items 1.02, 7.01, 9.01 · Accession 0001493152-26-032541
- 8-K
Current report
Items 2.03, 9.01 · Accession 0001493152-26-032151
- 3
Initial statement of beneficial ownership
Accession 0001493152-26-031457
- 8-K
Current report
Items 5.02, 9.01 · Accession 0001493152-26-031065
- 10-Q
Quarterly report
Accession 0001493152-26-028880
- 8-K
Current report
Items 2.03, 9.01 · Accession 0001493152-26-027265
- 8-K
Notice of delisting or failure to satisfy a listing rule
Items 3.01, 9.01 · Accession 0001493152-26-024600
- 8-K
Current report
Items 2.03, 9.01 · Accession 0001493152-26-021486
- 10-K
Annual report
Accession 0001493152-26-021108
- 8-K
Notice of delisting or failure to satisfy a listing rule
Items 3.01, 9.01 · Accession 0001493152-26-018216
- 8-K
Current report
Items 2.03, 9.01 · Accession 0001493152-26-015512
- NT 10-K
Late annual report notification
Accession 0001493152-26-014635
- 8-K
Current report
Items 2.03, 9.01 · Accession 0001493152-26-008853
- 8-K
Current report
Items 2.03, 9.01 · Accession 0001493152-26-006694
- SCHEDULE 13G/A
Amended beneficial ownership report (passive)
Accession 0001104659-26-013875
- SCHEDULE 13G/A
Amended beneficial ownership report (passive)
Accession 0001072613-26-000035
- 8-K
Current report
Items 2.03, 9.01 · Accession 0001493152-26-000589
- 8-K
Current report
Items 2.03, 9.01 · Accession 0001493152-25-026631
- 8-K
Entry into a material definitive agreement; Submission of matters to a vote of security holders; Other events
Items 1.01, 3.03, 5.03, 5.07, 8.01, 9.01 · Accession 0001493152-25-025731
- 10-Q
Quarterly report
Accession 0001493152-25-024062
- NT 10-Q
Late quarterly report notification
Accession 0001493152-25-023415
- 8-K
Submission of matters to a vote of security holders; Other events
Items 5.07, 8.01, 9.01 · Accession 0001493152-25-021585
- DEF 14A
Definitive proxy statement
Accession 0001493152-25-021405
- SCHEDULE 13G/A
Amended beneficial ownership report (passive)
Accession 0001140361-25-041137
Aimei Health Technology Co., Ltd.: questions answered
What is Aimei Health Technology Co., Ltd. (AFJK)?
Aimei Health Technology Co., Ltd. is a special purpose acquisition company incorporated and registered with the SEC under CIK 0001979005. It completed its initial public offering in Dec 2023 and listing on Nasdaq. Class A shares trade under the ticker AFJK, units under AFJKU, rights under AFJKR on Nasdaq. The vehicle is sponsored by Aimei through Aimei Investment Ltd. The mandate targets technology, healthcare. IPO closed, trust funded, no definitive agreement announced.
How much does Aimei Health Technology Co., Ltd. hold in trust?
Approximately $12,488,393, or about $12.00 per public share, as at the most recent filing on record. Trust balances move: shareholders redeem at extension votes and at the combination vote, and sponsors pay contributions in to extend. Treat the figure as a point-in-time disclosure, not a running balance.
When must Aimei Health Technology Co., Ltd. complete a merger?
No combination deadline appears in the filings we have indexed. The date is stated in the charter and repeated in each quarterly report; where our parser could not establish it with confidence we leave it blank rather than infer one.
What happens if Aimei Health Technology Co., Ltd. does not find a target in time?
The charter requires the vehicle to redeem 100% of the public shares and return the trust, pro rata, to public shareholders. That is the mechanism working as designed rather than a default. Founder shares and warrants are worthless in that outcome, which is why the sponsor's incentive is to get a deal done or to buy more time. Across the market, deadline lapsed without a deal; trust returned to public shareholders.
Can I redeem shares in Aimei Health Technology Co., Ltd., and at what price?
Public shareholders may elect to redeem in connection with a combination vote and at each extension vote, at the pro-rata trust value on the relevant record date, most recently disclosed at about $12.00 per share. Redemption is a right attached to the public shares only; warrants and rights carry no claim on the trust. The mechanics and the deadline for electing are set out in the proxy statement for the vote in question.
What tickers does Aimei Health Technology Co., Ltd. trade under?
Class A shares trade as AFJK on Nasdaq, the units as AFJKU, with rights as AFJKR. Units trade first and separate into their component securities roughly 52 days after the IPO; only the Class A shares carry the redemption right against the trust.
Is the trust value the same as the share price for Aimei Health Technology Co., Ltd.?
No, and the gap between them is the whole trade. Trust per share is a disclosed, contractual figure of $12.00, being what a redeeming holder receives. The market price is whatever the shares change hands at: most recently $12.51, a premium of 4.25% to the redemption value. Quotes on this site are delayed and indicative; confirm on your own venue before trading.
How much dilution do Aimei Health Technology Co., Ltd.'s founder shares and warrants create?
The founder block is 437,500 shares against 1,040,332 public shares, so roughly 29.6% of the combined count sits with the sponsor at nominal cost. Both are disclosed in the prospectus and both survive into the combined company, which is why a de-SPAC at $10 is not economically the same as an IPO at $10.
Who sponsors Aimei Health Technology Co., Ltd., and what is their track record?
Aimei Investment Ltd is the sponsor entity, part of the Aimei franchise. This is the only vehicle we have attributed to that sponsor. Named principals: Juan Fernandez.
Which banks underwrote the Aimei Health Technology Co., Ltd. IPO?
Spartan Capital, B. Riley Securities. Spartan Capital and B. Riley Securities were credited as book-running managers on the cover. Syndicate membership and role are read from the prospectus cover and the underwriting section.
Is Aimei Health Technology Co., Ltd. tradeable, and where?
Yes. AFJK returned a live quote of $12.51 on Nasdaq. Quotes here are delayed and refreshed on a schedule rather than streamed, so treat the figure as indicative and confirm on your own venue. Units and warrants trade under their own symbols and are quoted separately.
Is Aimei Health Technology Co., Ltd. a good investment?
That is not a question this site answers. Aimei Health Technology Co., Ltd. is covered here as reference data: what the company filed, when it filed it, and what the numbers in those filings say. The Edge, FOMO and Potential scores on this page are derived measures with a published formula, not ratings of investment merit: they describe the setup, and every component is shown so you can take them apart. We publish no price targets and no recommendations, and nothing here should be read as advice. The figures are a starting point for your own work, and each one carries the accession number of the filing it came from.
Where does this Aimei Health Technology Co., Ltd. data come from?
Filings Aimei Health Technology Co., Ltd. submitted to the SEC under CIK 0001979005: the registration statement and final prospectus for the structure, quarterly and annual reports for the trust, current reports and proxy statements for deals, votes and extensions. Trust economics are taken from the registrant's own XBRL tags rather than parsed from prose, which is why they are exact. Every filing in the history above is listed with its accession number, which identifies the document uniquely on EDGAR; Pro accounts open it directly from the row.
Compiled by the SPACListing research desk
Last reconciled Sep 4, 2026
Every figure on this page is read from documents the registrants filed with the U.S. Securities and Exchange Commission, principally the IPO prospectus (Form 424B4), quarterly and annual reports, current reports and proxy statements, the registrant's own XBRL tags for trust economics. Nothing is sourced from press coverage, from the companies themselves, or from a third-party aggregator. Where a filing does not disclose something, the field is left blank rather than estimated.
Read the full methodology · What is in the dataset · Report a correction
SPACListing is a reference-data service, not an investment adviser. Nothing here is a recommendation to buy or sell any security.
Continue reading
The context around this vehicle: who else the sponsor has launched, which banks priced it, and where it sits in the wider market.
Aimei: the full record
Every vehicle this sponsor has launched, what closed, what liquidated and what is still live.
Spartan Capital in SPACs
Mandates, bookrun credit, deal volume and the outcome of the vehicles it priced.
Technology SPACs
Every vehicle chasing the same mandate, ranked by cash in trust.
All spacs searching for a target
IPO closed, trust funded, no definitive agreement announced.
Deadline calendar
Which sponsors are running out of time, and when the extension votes land.
What is a SPAC?
The structure, the economics and where the risks actually sit.
SPAC glossary
Every term in a blank-check filing, defined the way practitioners use it.
How this data is built
Coverage universe, ingestion, normalisation, lifecycle classification and known limits.